Brief: Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study
26/05/2026 12:40
BRIEF-Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study May 26 (Reuters) - NervGen Pharma Corp NGEN.O:
NERVGEN PHARMA CORP - NVG-291 SHOWS STATISTICALLY SIGNIFICANT GAIT QUALITY IMPROVEMENT IN PHASE 1B/2A CONNECT SCI STUDY
NERVGEN PHARMA CORP - ON TRACK TO INITIATE PHASE 3 RESTORE STUDY IN MID-2026
Source text: ID:nGNX5bP3ML
Further company coverage: NGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nervgen Pharma
See all newsBrief: Nervgen Announces First Participant Dosed In Restore, A Phase 3 Registrational Study Evaluating NVG-291 In Chronic Spinal Cord Injury
Brief: NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Brief: Nervgen Reports Second Quarter 2026 Financial Results And Provides Business Updates
Brief: Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive